详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

The Chinese Stroke Association scientific statement: Intravenous thrombolysis in acute ischaemic stroke

文献详情

资源类型：

收录情况： ◇ SCIE

作者：

机构： [a]Department of Neurology, Huashan Hospital Affiliated to Fudan University, Shanghai Shi, China [b]Department of Neurology, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China [c]Department of Neurology and Stroke Center, First Affiliated Hospital, Jinan University, Guangzhou Shi, China

出处：

DOI：

ISSN：

摘要：

The most effective medical treatment for acute ischaemic stroke (AIS) is to offer intravenous thrombolysis during the ultra-early period of time after the onset. Even based on the Consensus of Chinese Experts on Intravenous Thrombolysis for AIS in 2012 and 2014 Chinese Guidelines on the Diagnosis and Treatment of AIS, the rate of thrombolysis for AIS in China remained around 2.4%, and the rate of intravenous tissue plasminogen activator usage was only about 1.6% in real world. The indication of thrombolysis for AIS has been expanded, and contraindications have been reduced with recently published studies. In order to facilitate the standardisation of treating AIS, improve the rate of thrombolysis and benefit patients who had a stroke, Chinese Stroke Association has organised and developed this scientific statement. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved.

基金：

competing interests The Chinese Stroke Association affirms the value of this scientific statement as an educational tool for neurologists. The members of the CSA Scientific Statement on Intravenous Thrombolysis in Acute Ischemic Stroke Writing Group make every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional or business interest of a member of the writing panel. QD is employed at Huashan Hospital; has received NSF grants; is part of the speakers' bureau and received honoraria from Boehringer Ingelheim, Pfizer and Sanofi-Aventis; has received consultancy fees/served in the advisory board of Boehringer Ingelheim, Pfizer and Sanofi-Aventis; and is associated with INTERACT II, PERFFORM, CHANCE and CSPPT Steering Committee. YD is employed at Huashan Hospital and is a recipient of IUCNSI, ISC young investigation travel award and WSO young physician exchange award. LL is employed at Tiantan Hospital; has received NSF grants; is part of the speakers' bureau and received honoraria from Boehringer Ingelheim, Pfizer and Sanofi-Aventis; has received consultancy fees/served in the advisory board of Boehringer Ingelheim, Pfizer and Sanofi-Aventis; and is associated with CHANCE, CNSR, SOCRATES, CSPPT, PRINCE and HR-NICE Steering Committee. AX is employed at The First Affiliated Hospital, Jinan University, Guangzhou; has received grants from National Natural Science Foundation of China (81671167), Science and Technology Program of Guangzhou (2014Y2-00505, 201508020004); is part of the speakers' bureau and received honoraria from Boehringer Ingelheim, Pfizer, Sanofi-Aventis, AstraZeneca and Bayer; has received consultancy fees/served in the advisory board of Boehringer Ingelheim, Pfizer, Sanofi-Aventis, AstraZeneca and Bayer; and is associated with CHANCE and SOCRATES Steering Committee. YZ is employed at The First Affiliated Hospital, Jinan University. HZ is employed at Tiantan Hospital; is supported by CCMAD; and is part of the speakers' bureau and received honoraria from Boehringer Ingelheim, Pfizer and Sanofi-Aventis. YW is employed at Tiantan Hospital; has received NSF grants; is part of the speakers' bureau and received honoraria from Boehringer Ingelheim, Pfizer and Sanofi-Aventis; has received consultancy fees/served in the advisory board of Boehringer Ingelheim, Pfizer and Sanofi-Aventis; and is associated with CHANCE, CNSR, SOCRATES, CSPPT, PRINCE and HR-NICE Steering Committee. patient consent Obtained. provenance and peer review Not commissioned; externally peer reviewed.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2016]版：

无

最新[2023]版：

大类 | 1 区医学

小类 | 2 区临床神经病学

JCR分区：

出版当年[2015]版：

无

最新[2023]版：

Q1 CLINICAL NEUROLOGY

影响因子： 4.4 最新[2023版] 6 最新五年平均 0 出版当年[2015版] 0 出版当年五年平均 0 出版前一年[2014版]

第一作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：